A 24-gene prognostic signature identifies CHEK1 as a curcumin-responsive biomarker in lung adenocarcinoma

Introduction Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer and carries a poor prognosis, with intratumor heterogeneity limiting the durability of current chemotherapeutics. Curcumin displays broad antitumor activity, but the effectors through which it acts in LUAD are unresolved, and network pharmacology studies typically terminate at untested hub-gene lists. Here, we narrow such a list rather than extend it. Methods Candidate curcumin targets from six prediction databases were intersected with differentially expressed genes from five LUAD microarray series. Shared targets were filtered by topology and co-expression, then phenotype-ranked; in parallel, univariate Cox screening in TCGA-LUAD was followed by elastic net regression, validation in two independent cohorts without refitting, docking of genes common to both routes, and testing of the leading candidate in A549 cells with curcumin of verified purity. Results & discussion Intersection yielded 224 shared targets enriched for the regulation of programmed cell death and protein phosphorylation. Topological screening returned 52 hub targets, 49 co-expressed, and 19 phenotype-linked. Of 219 evaluable targets in TCGA-LUAD (n = 481, 174 deaths), 81 were survival-associated, from which elastic net regression derived a 24-gene signature separating high- and low-risk groups. The signature retained prognostic value in both validation cohorts [GSE72094, n = 398, adjusted hazard ratio (HR) per standard deviation 1.49, 95% CI 1.24–1.79; GSE31210, n = 226, adjusted HR 1.60, 95% CI 1.17–2.19], remaining significant after adjustment for tumor stage, indicating information not captured by staging. CHEK1, SMAD3, and KIT were common to both sets, which share no filtering step, so their intersection is convergent evidence; docking returned −8.3 and −6.2 kcal/mol for CHEK1 and SMAD3, CHEK1 being the more druggable. Curcumin reduced A549 viability in a time- and dose-dependent manner and lowered CHEK1 transcript and protein abundance at a sub-cytotoxic concentration, reflecting signaling modulation rather than loss of viable cells. Conclusion: CHEK1 is a prognostically informative, phenotype-linked, and experimentally responsive candidate effector of curcumin in LUAD, and this framework converts network-derived target lists into testable hypotheses. Causal dependence on CHEK1 was not established and will require genetic perturbation.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-20
DOI
https://doi.org/10.3389/fonc.2026.1987994
Primary Topic
Curcumin's Biomedical Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A 24-gene prognostic signature identifies CHEK1 as a curcumin-responsive biomarker in lung adenocarcinoma

Syed Mansoor Ali, Kapil Dev, Fazlur Rahman, Wesam Nofal et al.
Frontiers in Oncology
Curcumin's Biomedical Applications
article

A 24-gene prognostic signature identifies CHEK1 as a curcumin-responsive biomarker in lung adenocarcinoma

Syed Mansoor Ali, Kapil Dev, Fazlur Rahman, Wesam Nofal, Abdulaziz Asiri, Abdulaziz A. Aloliqi, Amer Al Ali, Mohammad Zeeshan Najm
article en

Abstract

Introduction Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer and carries a poor prognosis, with intratumor heterogeneity limiting the durability of current chemotherapeutics. Curcumin displays broad antitumor activity, but the effectors through which it acts in LUAD are unresolved, and network pharmacology studies typically terminate at untested hub-gene lists. Here, we narrow such a list rather than extend it. Methods Candidate curcumin targets from six prediction databases were intersected with differentially expressed genes from five LUAD microarray series. Shared targets were filtered by topology and co-expression, then phenotype-ranked; in parallel, univariate Cox screening in TCGA-LUAD was followed by elastic net regression, validation in two independent cohorts without refitting, docking of genes common to both routes, and testing of the leading candidate in A549 cells with curcumin of verified purity. Results & discussion Intersection yielded 224 shared targets enriched for the regulation of programmed cell death and protein phosphorylation. Topological screening returned 52 hub targets, 49 co-expressed, and 19 phenotype-linked. Of 219 evaluable targets in TCGA-LUAD (n = 481, 174 deaths), 81 were survival-associated, from which elastic net regression derived a 24-gene signature separating high- and low-risk groups. The signature retained prognostic value in both validation cohorts [GSE72094, n = 398, adjusted hazard ratio (HR) per standard deviation 1.49, 95% CI 1.24–1.79; GSE31210, n = 226, adjusted HR 1.60, 95% CI 1.17–2.19], remaining significant after adjustment for tumor stage, indicating information not captured by staging. CHEK1, SMAD3, and KIT were common to both sets, which share no filtering step, so their intersection is convergent evidence; docking returned −8.3 and −6.2 kcal/mol for CHEK1 and SMAD3, CHEK1 being the more druggable. Curcumin reduced A549 viability in a time- and dose-dependent manner and lowered CHEK1 transcript and protein abundance at a sub-cytotoxic concentration, reflecting signaling modulation rather than loss of viable cells. Conclusion: CHEK1 is a prognostically informative, phenotype-linked, and experimentally responsive candidate effector of curcumin in LUAD, and this framework converts network-derived target lists into testable hypotheses. Causal dependence on CHEK1 was not established and will require genetic perturbation.

Frontiers in OncologyVol. 16
Northern Border University (SA), Qassim University (SA), Apeejay Stya University (IN), University of Bisha (SA), Jamia Millia Islamia (IN)
University of Bisha
Good health and well-being
Curcumin's Biomedical Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon